Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Correction: Calcium electroporation for treatment of sarcoma in preclinical studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  3. Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The collagen receptor uparap in malignant mesothelioma: A potential diagnostic marker and therapeutic target

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Novel Combination Treatments for AML

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Osteosarcoma and Metastasis Associated Bone Degradation-A Tale of Osteoclast and Malignant Cell Cooperativity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

A key task in developing the field of personalized cancer therapy is the identification of novel molecular targets that enable treatment of cancers not susceptible to other means of specific therapy. The collagen receptor uPARAP/Endo180 is overexpressed by malignant cells in several non-epithelial cancers, notably including sarcomas, glioblastomas and subsets of acute myeloid leukemia. In contrast, in healthy adult individuals, expression is restricted to minor subsets of mesenchymal cells. Functionally, uPARAP/Endo180 is a rapidly recycling endocytic receptor that delivers its cargo directly into the endosomal-lysosomal system, thus opening a potential route of entry into receptor-positive cells. This combination of specific expression and endocytic function appears well suited for targeting of uPARAP/Endo180-positive cancers by antibody-drug conjugate (ADC) mediated drug delivery. Therefore, we utilized a specific monoclonal antibody against uPARAP/Endo180, raised through immunization of a uPARAP/Endo180 knock-out mouse, which reacts with both the human and the murine receptor, to construct a uPARAP-directed ADC. This antibody was coupled to the highly toxic dolastatin derivative, monomethyl auristatin E, via a cathepsin-labile valine-citrulline linker. With this ADC, we show strong and receptor-dependent cytotoxicity in vitro in uPARAP/Endo180-positive cancer cell lines of sarcoma, glioblastoma and leukemic origin. Furthermore, we demonstrate the potency of the ADC in vivo in a xenograft mouse model with human uPARAP/Endo180-positive leukemic cells, obtaining a complete cure of all tested mice following intravenous ADC treatment with no sign of adverse effects. Our study identifies uPARAP/Endo180 as a promising target for novel therapy against several highly malignant cancer types.

OriginalsprogEngelsk
TidsskriftOncotarget
Vol/bind8
Udgave nummer27
Sider (fra-til)44605-44624
Antal sider20
ISSN1949-2553
DOI
StatusUdgivet - 4 jul. 2017

ID: 52425427